Company Valuation: Tibet Rhodiola Pharmaceutical Holding Co.

Data adjusted to current consolidation scope
Fiscal Period: December 2020 2021 2022 2023 2024 2025
Market Cap 1 16,681 12,982 8,906 12,099 11,906 13,715
Change - -22.18% -31.4% 35.86% -1.59% 15.19%
Enterprise Value (EV) 1 15,908 12,218 7,462 10,226 9,555 11,106
Change - -23.19% -38.93% 37.05% -6.56% 16.23%
P/E 39.8x 62.3x 24.1x 15.1x 11.3x 14.6x
PBR 6.48x 4.94x 2.96x 3.62x 3.04x 3.61x
PEG - -1.2x 0.3x 0x 0.4x -1.4x
Capitalization / Revenue 12.1x 6.07x 3.49x 3.86x 4.24x 4.6x
EV / Revenue 11.6x 5.71x 2.92x 3.26x 3.4x 3.72x
EV / EBITDA 32.8x 18.7x 9.85x 9.25x 9.87x 11.1x
EV / EBIT 39.1x 21.3x 10.8x 9.85x 10.7x 12x
EV / FCF 207x -208x 16.3x 17.5x 19.8x 15.9x
FCF Yield 0.48% -0.48% 6.14% 5.73% 5.06% 6.28%
Dividend per Share 2 0.3923 0.26 0.5738 1.492 1.957 1.757
Rate of return 0.76% 0.65% 2.08% 3.97% 5.3% 4.13%
EPS 2 1.3 0.6462 1.146 2.485 3.26 2.91
Distribution rate 30.2% 40.2% 50.1% 60% 60% 60.4%
Net sales 1 1,373 2,139 2,555 3,134 2,807 2,982
EBITDA 1 485 654.2 757.5 1,105 967.6 1,002
EBIT 1 407.3 572.7 688.3 1,039 893.4 924.7
Net income 1 418.1 208.9 369.8 800.9 1,051 937.9
Net Debt 1 -773.1 -763.6 -1,444 -1,873 -2,351 -2,609
Reference price 2 51.75 40.28 27.63 37.54 36.94 42.55
Nbr of stocks (in thousands) 322,319 322,319 322,319 322,319 322,319 322,319
Announcement Date 11/03/21 11/03/22 10/03/23 26/03/24 14/03/25 12/03/26
1CNY in Million2CNY
Estimates

P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
- - - - 1.87B
34.93x12.78x25.81x0.56% 1,098B
29.12x - - 2.05% 631B
31.66x7.38x15.33x2.77% 438B
20.79x4.93x12.21x2.68% 368B
22.24x5.75x14.34x2.79% 298B
20.77x4.28x12.16x2.05% 251B
26.18x6.87x12.22x2.42% 226B
13.88x4.98x10.54x3.66% 209B
-41.32x5.92x33.42x2.48% 165B
Average 17.58x 6.61x 17.00x 2.38% 368.62B
Weighted average by Cap. 25.00x 8.33x 18.79x 1.95%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Stocks
  3. 600211 Stock
  4. Valuation Tibet Rhodiola Pharmaceutical Holding Co.